CD8A and neoplasm: This latter feature led to our hypothesis that even the lowest dose of SQZ-PBMC-HPV could be biologically active, a point demonstrated in the observed increases in tumor infiltrating CD8+ cells for a participant in the Low Dose – Single Prime cohort who experienced clinical benefit.